CLINICAL_TRIALS trial_result · 2012-08-22

Clinical Trial Update: CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse [Phase 2]

Pfizer's CMA-676 was studied in older patients with acute myeloid leukemia in first relapse in a Phase 2 trial. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Leukemia | Phase 2 | Status: COMPLETED